Effect of the metabolic syndrome on organ damage and mortality in patients with systemic lupus erythematosus: a longitudinal analysis

Objective To study the effect of the metabolic syndrome (MetS) on organ damage and mortality in patients with SLE. Methods Consecutive patients who fulfilled >= 4 ACR criteria for SLE were assessed for the MetS in October 2010. The MetS was defined by the updated joint consensus criteria, using the Asian criteria for central obesity. Longitudinal data on organ damage and mortality were retrieved. The association between MetS and new damage and mortality was studied by logistic regression. Results A total of 577 SLE patients were followed (93% women; age 41.2 +/- 13 .4 years; SLE duration 93 +/- 7.2 years) and 85 (14.7%) patients qualified the MetS. After a follow-up of 663 +/- 1.8 month, new organ damage and vascular events developed in 128(22%) and 23(4.0%) patients, respectively. Thirty-nine (6.8%) patients succumbed. Patients with the MetS, compared to those without, had significantly more SLICC damage score accrual (0.70 +/- 1.0 vs. 026 +/- 0.6; p<0.001), new vascular events (11% vs. 2.8%v; p=0.001), all-cause (14% vs. 5.5%; p=0.003) and vascular (7.1% vs. 0.2%; p<0.001) mortality. Logistic regression revealed that the MetS was significantly associated with new damage in the renal (OR 5.4812.06-14.61; p=0.001) and endocrine system (OR 38.014.50-321]; p=0.001), adjusted for age, sex, SLE duration, ever smoking, antiphospholipid antibodies and the new use of glucocorticoids or hydroxychloroquine since recruitment. Moreover, the presence of the MetS also significantly increased the risk of new vascular events (OR 3.38[1.31-8.74]:p=0.01) and vascular mortality (OR 28.3[3.24-247]; p=0.002) after adjustment for the same covariates. Conclusion In this longitudinal study, the MetS is significantly associated with new organ damage, vascular events and mortality in patients with SLE.